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Introduction An association between the R.E.N.A.L. nephrometry score (RNS) and clinical outcomes  
in patients with a small renal mass (SRM) has been proposed. We analyzed clinical outcomes according  
to the RNS in patients with a SRM treated with percutaneous contrast enhanced ultrasound (CEUS) 
radiofrequency ablation (RFA).
Material and methods Patients with a SRM, who underwent RFA between January 2005 and March 
2015, were retrospectively identified. The association between RNS and clinical outcomes was evaluated 
using parametric and non-parametric analysis.
Results We analyzed 163 SRMs in 149 consecutive patients. The mean age was 71.7 years. Mean follow-
up time was 33.3 months ±20.6 (2–102). The mean RNS was 5.6 ±1.52 (4–11). A total of 121 (74.2%) 
cases were of low complexity and 42 (25.8%) were medium complexity. We identified 11 cases of tumor 
persistence (6.7%). The mean RNS was 5.58 in the cases with no persistence and 5.73 in the cases with 
persistence (p = 0.788). We identified 15 (9.2%) cases of recurrence. The mean RNS was 5.57 ±0.1 (4–11) 
in the cases without recurrence and 5.73 ±0.4 (4–9) in recurrence cases (p = 0.804). Of the 76 biopsy 
proven RCC cases, 8 (10.5%) cases of recurrence were observed, 5 in the low complexity group and 3  
in the medium complexity group (p = 0.690). A total of 9 (5.5%) cases of complications were observed, 
with 5 (4.3%) in the low complexity group and 4 cases in the medium complexity group (p = 0.23).  
The mean length of stay was 1.5 days with a significant difference between low and medium complexity 
groups (1.3 vs. 2.1 days, p = 0.02). The mean difference between preoperative eGFR and estimated eGFRat 
12 months was -3.08 mL / min ±13.3 (-49.4–34.1) and was significant (p = 0.008).However, this variation 
did not show significant differences between the low and medium complexity groups (p = 0.936). All-
cause mortality was 11.7%, 14 cases (11.6%) in the low complexity group and 5 (11.9%) in the medium 
complexity group (p = 1.0). No cases of renal cell carcinoma (RCC) specific mortality were identified.
Conclusions The RNS was not associated with tumor persistence, recurrence, cancer specific mortality, 
complications or renal function 12 months after the first treatment, showing significant difference only  
in length of hospital stay between low and medium complexity groups.
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Spain between January 2005 and March 2015 were 
prospectively enrolled in this study. Institutional re-
view board ethics approval was obtained. Patients 
were initially evaluated by a urologist to determine 
and counsel about the best treatment strategy. If ab-
lation was decided upon, the patient was referred to 
an interventional radiologist for feasibility assess-
ment using CEUS. Patients lacking digital images or 
other relevant data were excluded. Unless obtained 
beforehand, a simultaneous renal mass biopsy was 
incorporated into routine practice, particularly 
in later years. The biopsy was obtained during the 
RFA ablation, thus, the final pathology report was 
revealed afterwards. We used a 15 cm electrode-
needle Cool-Tip TM RF ablation system under con-
scious sedation plus local anesthesia. When a biopsy 
was performed, an 18 G needle was used. If required, 
a bowel hydrodissection, transhepatic approach or 
a cold saline solution irrigation through an ureter-
al tube were performed. The technique used in our 
center was described in detail by Trilla et al. in 2017 
[12]. Patients were evaluated in the urology clinic 
at 3, 6 and 12 months after treatment for the first 
year, then every 6 months for the following 4 years 
and yearly follow-ups thereafter, assessing clini-
cal condition, renal function and imaging including 
a computed tomography (CT) scan and/or CEUS.
Outcomes and definitions
 Tumor persistence was defined as the presence 
of a contrast enhanced nodule or soft tissue in the 
treated area at the first 3 month control. The treat-
ment was considered successful with the absence 
of these findings. 
 Oncological outcomes
 Recurrence, defined as a contrast enhanced 
nodule or soft tissue in the treated area after 
a negative first control. 
 Metastasis 
 Cancer specific mortality (CSM) and all-cause 
mortality (ACM).
 Complications, according to the Clavien–Dindo 
system and length of hospital stay.
 Functional results, using serum creatinine lev-
els to calculate estimated glomerular filtration 
rate (eGFR) according to the Modification of Diet 
in Renal Disease formula. Levels at pre-treatment 
and at the 12 month follow-up were compared.
Statistical analysis 
Clinicopathological data and outcomes were ana-
lyzed using descriptive statistics. Outcomes and 
R.E.N.A.L. nephrometry scores were compared us-
INTRODUCTION
The incidence of renal cell carcinoma (RCC) has in-
creased significantly in the last 50 years [1]. In Eu-
rope in 2008 there were 88 400 new cases and 39 300 
kidney cancer-related deaths per year [2]. Nephron 
sparing approaches (NSA) using minimally invasive 
techniques are highly precise procedures specialized 
for small renal masses (SRM), which are defined 
as incidentally detected, contrast-enhancing renal 
tumors ≤4 cm in diameter [3]. While partial nephrec-
tomy (PN) is the new gold standard of care for T1 
RCC, there is a group of patients unfit for surgery 
given their short life expectancy, co-morbidities 
or denial. In response to the need for NSA in patients 
unfit for surgery, there has been an increasing inter-
est in percutaneous ablation techniques such as ra-
diofrequency ablation (RFA) and cryoablation (CA). 
RFA for the treatment of kidney tumors was initially 
described by Zlotta et al. in 1997 [4] and consists of 
transferring alternating monopolar radiofrequency 
electrical currents through needle electrodes into 
the target tissue, which results in ionic agitation, 
heating, and eventual desiccation with sub-sequent 
coagulative necrosis [5]. 
During recent years, our knowledge has expanded 
regarding the influence of the tumor's anatomical 
complexity, rather than just the diameter, on clini-
cal outcomes in terms of treatment for RCC by NSA 
[6, 7]. In order to measure and standardize that com-
plexity, Kutikov and Uzzo developed the R.E.N.A.L. 
Nephrometry Score (RNS) in 2009 [8] which assigns 
points for size, location and depth of renal tumors, 
classifying complexity into low (4–6), medium (7–9) 
and high (10–12). 
Contrast enhanced ultrasound (CEUS) is a real-time 
dynamic imaging technique that plays an important 
role in the management of patients treated with ab-
lation for malignant tumors. Characterization of re-
nal masses and cyst lesions is a well-established in-
dication for CEUS [9]. In patients undergoing renal 
percutaneous tumor ablation, CEUS may be used 
as a pre-treatment evaluation to improve lesion vi-
sualization in difficult cases, to guide the placement 
of ablation devices and to detect residual tumors, ei-
ther immediately or later after ablation [10, 11]. 
In the present study we analyzed the association 
between the RNS and clinical outcomes in patients 
with SRM treated with percutaneous RFA guided 
by CEUS. 
MATERIAL AND METHODS
Patients who underwent percutaneous CEUS guid-
ed RFA performed in a single hospital in Barcelona, 
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ing Fisher's test for categorical variables and Mann 
Whitney's and Wilcoxon's test for quantitative vari-
ables. Kaplan–Meier analyses was performed for 
overall, cancer-specific and local recurrence-free 
survival. Statistical significance was set at p ≤0.05. 
SPSS software version 20.0 was used. 
RESULTS
A total of 182 procedures were performed in a sam-
ple of 166 consecutive patients. We excluded 19 cases 
as we did not have the images necessary to calculate 
the RNS, which could be obtained in the 163 cases 
(89.5%) in the 149 (89.8%) patients who were includ-
ed in the analysis. Cohort characteristics are sum-
marized in Table 1. The mean age was 71.7 years 
and 69.1% were men. Mean follow-up time was 33.3 
months ±20.6 (2–102). The mean RNS was 5.6 ±1.52 
(4–11), 4.8 ±0.8 (4–6) in the low complexity group 
and 7.8 ±0.9 (7–11) in the medium complexity group 
(p ≤0.001). Given that only one case was highly com-
plex as determined by the RNS, this single case was 
included from the average complexity group. Thus, 
121 cases were of low complexity and 42 of medium 
complexity. 
Tumor persistence
We identified 11 cases of tumor persistence (6.7%). 
The mean size of the tumors in the non-persistent 
cases was 2.6 cm whereas in those with persistence 
it was 3.3 cm (p = 0.01). The mean RNS was 5.58 in 
the cases with no persistence and of 5.73 in the cases 
with persistence (p = 0.788). Of the 121 cases of low 
complexity, 8 (6.6%) had tumor persistence, whereas 
of the 42 cases of medium complexity, 3 (7.1%) had 
tumor persistence (p = 0.57) (Table 2). The 11 cases 
of persistence were submitted to a second treatment, 
Characteristc Whole cohort Low RNS Medium RNS p-value
Patients1 149 (100) 108 (72.5) 41 (27.5)
Age (years)2 71.7 ±10.7 (36–92) 71.4 ±11.3(36–92)
72.5 ±9.0
(50–86) 0.742
Male1 103 (69.1) 74 (68.5) 29 (70.7)
0.480
Female1 46 (30.9) 34 (31.5) 12 (29.3)





Right Kidney1 81(49.7) 65 (53.7) 16 (38.1)
0.167
Left Kidney1 81 (49.7) 55(45.5) 26 (61.9)
Renal graft1 1 (0.6) 1 (0.8) 0
Procedures1 163 (100) 121(74.2)
42
(25.8)





Biopsy during procedure1 129 (79.1) 95 (73.6) 34 (26.4) 34 (26.4)
Tumor characteristics





– Benign1 46 (35.7) 36 (37.9) 10 (29.4) 0.208
– RCC1 76 (58.9) 53 (55.8) 23 (69.7) 0.158
– Papillary1 20 (26,3) 16 (28,5) 4 (17,4)
0.256
– Clear cell1 39 (51,3) 26 (49,1) 13 (56,5)
– Chromophobe1 11 (14.5) 6 (11.3) 5 (21.7)
– Mucinous tubular1 1 (1.3) 0 1 (4.3)
– Indeterminate1 5 (6.6) 5 (9.4) 0
– Non–diagnostic biopsy1 7 (5.4) 6 (6.3) 1 (2.8)
1: n (%); 2: mean ±SD (min-max). 
RNS – RENAL nephroemtry score; eGFR – estimated glomerular filtration rate; RCC – Renal cell carcinoma
Table 1. General characteristics of the whole cohort according to RNS
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re-treated with RN with final pathology diagnosis 
of RCC-clear cell, one re-treated with RFA and 
2 not re-treated). No significant difference was ob-
served in recurrence rates between these 3 groups 
(p = 0.344). Overall, 11 cases of recurrence were 
subjected to a second treatment, 10 RFA and 1 RN. 
In the remaining 4 cases, active surveillance was 
chosen considering the patients’ general condition 
and life expectancy. The mean size of the tumors 
in cases without recurrence was 2.6 cm ±0.1 (1.2–4.9) 
whereas in those with relapse it was 3.2 cm ±0.2 
(1.9–4.7) (p = 0.02). The mean RNS was 5.57 ±0.1 
9 of them through a second RFA and 2 cases with 
PN. 3 cases presented a relapse after re-treatment. 
2 of them were treated with a new RFA while in one 
case a radical nephrectomy (RN) was performed.
Tumor recurrence
We identified 15 (9.2%) cases of tumor recurrence, 
8 biopsy proven RCCs (7 re-treated, with RFA), 3 ini-
tially reported as benign (2 Oncocytomas, both re-re-
treated with RFA and one initially reported with no 
evidence, not re-treated) and 4 indeterminate (one 
Characteristc Whole cohort Low RNS Medium RNS p-value
Complications1 9 /163 (5.5) 5/121 (4.1) 4/42 (9.5) 0.230




















Persistence1 11/163 (6.7) 8/121 (6.6) 3/42 (7.1) 0.570
Recurrence1 15/163 (9.2) 10/121 (8.3) 5/42 (11.9) 0.530
Recurrence*1 8/76 (10.5) 5 /53 (9.4) 3/23 (13) 0.690
ACM 11.7 % 11.6 % 11.9 % 1.000
1 n/total (%); 2 mean ±DS (min-max); 2 n (%); *only RCC biopsy proven
RNS – RENAL nephrometry score; eGFR – estimated glomerular filtration rate; ACM – all cause mortality
Table 2. Main outcomes of the whole cohort according to RNS
Figure 1. Recurrence-free survival (Kaplan-Meier) according to R.E.N.A.L nephrometry score.
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Complications and length of stay
A total of 9 (5.5%) cases of complications were ob-
served, 5 cases of 121 (4.3%) in the low complexity 
group and 4 of 42 (9.5%) cases in the medium com-
plexity group (Table 2) (p = 0.23). In the uncompli-
cated group, the mean RNS was 5.5 ±0.12 (4–11), 
while in the group with complications the mean RNS 
was 6.33 ±0.5 (5–9) (p = 0.097). In the uncomplicat-
ed group the mean tumor diameter was 2.7 cm ±0.1 
(1.2–4.9) whereas in the group with complications 
the mean tumor diameter was 3.3 cm ±0.5 (1.6–4.9) 
(p = 0.071). 5 complications were Clavien 1, 3 were 
Clavien 2 and 1 case was Clavien 3a (Table 3). The 
mean length of stay was 1.5 days for the whole group, 
with a significant difference between low and medi-
um complexity groups (1.3 vs. 2.1 days, p = 0.02).
Renal function 
There were 8 patients who were on hemodialysis pri-
or to ablation, so they were excluded from the analy-
sis of renal function. During follow-up 7 patients un-
derwent renal replacement therapy (RRT), 6 of them 
in a hemodialysis program while 1 patient received 
a renal transplant. Only 1 patient required RRT 
during the first year of follow-up. The mean preop-
erative eGFR was 66.6 ±25.2 (15.0–159.8), in the 
low complexity group it was 64.3 ±2.6 (15.8–159.8) 
and in the medium complexity group, 72.1 +4.4 
(15.0–114.3) (p = 0.298), while eGFR at 12 months 
post-ablation was 63.4 mL/min +25.9 (8.6–138.8), 
in the low complexity group, 61.2 mL/min +2.6 
(8.6–138.8) and in the medium complexity group, 
69.2 +4.6 (8.6–119.8) (p = 0.105). The mean dif-
ference between preoperative eGFR and estimat-
ed eGFR at 12 months was -3.08 mL/min +13.3 
(-49.4–34.1) which was significant, (p = 0.008) how-
ever, this variation did not show significant differ-
ences between the low and medium complexity 
groups (p = 0.936) (Table 2).
(4–11) in the cases without recurrence and 5.73 
±0.4 (4–9) in cases with recurrence (p = 0.804). 
Of the 121 cases of low complexity, 10 (8.3%) had tu-
mor recurrence, whereas, of the 42 cases of medium 
complexity, 5 (11.9%) had recurrence (p = 0.53). 
Of the 76 biopsy proven RCC cases, 8 (10.5%) cases 
of recurrence were observed, 5 in the low complex-
ity group and 3 in the medium complexity group 
(p = 0.690). No significant differences of recurrence 
were observed among RCC subtypes (p = 0.927). 
Overall recurrence-free survival (RFS) and biopsy 
proven RCC group RFS according to RNS are pre-
sented in Figure 1. 
Metastasis
One case (1.3% of biopsy-proven RCC group) of nodal 
metastasis was identified at 12 months after the ini-
tial treatment in a patient with tumor persistence 
that had been re-treated by PN. The initial tumor 
was 2 cm with a RNS of 4. Biopsy of the tumor 
showed a clear cell RCC Fuhrman grade 2.
Mortality 
In total there were 19 deaths (11.7%), 14 (11.6%) in 
the low complexity group and 5 (11.9%) in the medi-
um complexity group (p = 1.0). No significant differ-
ence was observed in mortality regarding the initial 
pathology report (7 RCC, 6 benign and 6 without bi-
opsy, p = 0.353). No cases of RCC-specific mortality 
were identified. Overall survival according to RNS is 
presented in Figure 2. 





Subcapsular Haematoma 1 3 2 5
Subcapsular Haematoma 2 0 2 2
Abdominal collection 2 1 0 1
Skin burns 3a 1 0 1
Total 5 4 9
RNS – R.E.N.A.L. nephrometry score
Table 3. Description of complications according to the RNS and 
Clavien-Dindo System
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ly with CT guided percutaneous RFA reporting that 
maximum tumor diameter was the strongest predic-
tor of local recurrence with a Harrell C index = 0.81 
while RNS was found to be significantly predictive 
but showing poor performance with a Harrell C in-
dex = 0.68, limiting its overall utility in the authors’ 
opinion [29]. Neither pathology report nor subtype 
of RCC were associated with recurrence nor mortal-
ity, which is consistent with previous research, find-
ing that 64–84% of SRM are indolent tumors. Con-
trarily, a significant proportion of patients with SRM 
who progress to metastatic cancer are not identified 
by current pathological techniques. New technol-
ogy in imaging and molecular analysis are currently 
in development to address this issue [30]. 
We had only one case of metastatic progression, how-
ever, it was in a patient who had a small (2 cm), low 
RNS and low Fuhrman's grade tumor, which is con-
cerning considering our current understanding that 
SRMs rarely provoke metastatic disease when sized 
<3 cm [25]. Minardi et al. studied 48 patients with 
a pT1a RCC treated with PN finding that distant 
metastatic disease occurred in 2.4% of patients with 
tumors <3 cm versus 8.4% of patients with tumors 
between 3.1 cm and 4 cm, which is concordant with 
our results [31].
We observed an ACM of 11.7% without statistical dif-
ference between low and medium RNS groups.
Our complication rate of 5.5% is within the range 
of the 5.1–37% reported by the Vollherbst et al. Sys-
tematic review [24]. RNS and tumor diameter were 
larger in the cases with complications, however 
no significant difference was found. Length of hos-
pital stay was the only issue significantly associated 
with RNS. Tumor diameter or size has been con-
sidered a significant factor influencing the proce-
dure's safety. In the Camacho et al. study, a diameter 
>2 cm and a RNS >8 were significantly correlat-
ed with the presence of complications while in the 
Schmit et al. study, the RNS was found to be signifi-
cantly higher (8.1 vs. 6.8, p = 0.001) comparing pa-
tients with and without major complications. Again, 
the lack of a high complexity group in our study 
could explain these differences. 
We observed a slight but significant decrease of 
eGFR one year after the first RFA which reflects 
the fragility of this population. No significant differ-
ence was observed between RNS groups. Lucas et al. 
studied renal function in patients with RCC, finding 
that patients treated with RN were 34.3 times more 
likely to develop stage 3 chronic renal disease than 
patients treated with PN or percutaneous RFA [32]. 
In our study, one patient was successfully treated by 
renal graft. Cool et al. studied outcomes and graft 
viability after percutaneous RFA of 12 biopsy-proven 
DISCUSSION
Since the first publication of the RNS, there have 
been many articles showing a significant association 
with several clinical outcomes [13] such as surgi-
cal approach [14], surgical complications [15], renal 
functional outcome [16], ischemia time [17], histol-
ogy [18] and hospital stay, [19] however there is still 
little evidence regarding percutaneous ablative tech-
niques with contradictory results [20–23]. 
We observed a 6.7% tumor persistence rate, which 
is slightly higher than the 5.9% reported in the sys-
tematic review performed by Vollherbst et al. [24] 
but lower than the 13% reported by Ptsuka et al. 
[25]. We observed that tumor median size was sig-
nificantly higher in patients with persistence. Us-
ing a CT guide, Ianuccilli et al. studied 203 biopsy-
proven, percutaneous RFA findings that tumor size 
≥3.5  cm confers a significantly increased risk for 
residual tumors [26]; whereas Wah et al. found, 
in a multivariate, logistic regression analysis of 200 
percutaneous RFA, that two independent predictors 
of successful RFA in a single setting were tumor size 
(<3 cm) and exophytic location [27]. The RNS was 
higher in patients with tumor persistence but this 
difference was not significant. Concordantly, the lo-
cal failure ratio reported by Bhindi et al. using CA 
(defined as failure of the ablation ice ball to extend 
beyond the tumor margin on monitoring CT imaging 
during the procedure) was also not associated to the 
RNS [23]. 
We found a recurrence rate of 9.2% (10.5% in biopsy 
proven cases) which is on the higher end of the in-
terval observed in literature according to the Voll-
herbst et al. systematic review [24]. Tumor size was 
significantly higher in patients with recurrence. The 
RNS was higher in patients with recurrence but this 
difference was not significant. These findings are 
not concordant with the results of Camacho et al. 
who studied 101 biopsy proven SRMs treated with 
CA (54%) or RFA (46%) and reported a significant 
correlation between recurrence and a RNS >8 [28]. 
In another study performed by Schmit et al., 751 
renal tumors were treated using a percutaneous ap-
proach with CA (57%) or RFA (43%) and retrospec-
tively categorized regarding the RNS, finding that 
mean RNS was 7.6 versus 6.9 in patients with or with-
out treatment failure respectively (p = 0.001). These 
differences may be explained by the lack of a high 
complexity group in our study whereas the Camacho 
et al. study had 61 low, 26 medium and 14 high pa-
tients regarding the RNS and the Schmit et al. study 
had 351, 330 and 70 low, medium and high complex-
ity cases respectively. On the other hand, Maxwell 
et al. studied 217 biopsy-proven SRMs treated main-
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we performed a retrospective analysis reflecting the 
experiences within the first ten years of a single hos-
pital. Only in 79% of our treatments was a biopsy 
sample obtained as this was not part of our protocol 
in the beginning. Also, we had a lack of a high com-
plexity group according to the RNS which could have 
influenced our results; having a very homogeneous 
sample of patients could have prevented us from 
finding more significant outcomes.
CONCLUSIONS
In conclusion, percutaneous CEUS-RFA is a fea-
sible technique with excellent functional and onco-
logical outcomes and low rate of complications. The 
RNS was not associated with tumor persistence, 
recurrence, cancer specific mortality, complications 
or renal function showing significant difference only 
in length of hospital stay between low and medium 
complexity groups.
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RCC developing within renal transplant allografts. 
The authors reported 100% technical success and no 
recurrence nor progression after a mean follow-up 
of 54 months with no significant difference in eGFR 
previous to and 6 months after the procedure [33]. 
According to the European Federation of Societies 
for Ultrasound in Medicine and Biology (EFSUMB) 
guidelines, the use of CEUS can be useful in the man-
agement of RCC patients undergoing ablation proce-
dures due to the improved visualization of ambigu-
ous tumors, the assessment of therapeutic efficacy 
within 24 h after ablation, the detection of unablated 
tumors and local tumor progression, and the ability 
to guide re-ablation of recurrent viable tissue [10]. 
In our study, all cases had a first evaluation by the 
same radiologist who performed the procedure, as-
sessing the reliability of the treatment. During the 
procedure, CEUS was used to guide the needle and 
to evaluate the ablation's success in difficult cases. 
In our follow-up protocol CT scan and CEUS were 
used, however, we did not evaluate the concordance 
between CT and CEUS to detect recurrence.
Our study has several limitations. First of all, 
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